0.94
-0.0071(-0.75%)
Currency In USD
| Previous Close | 0.95 |
| Open | 0.94 |
| Day High | 0.98 |
| Day Low | 0.94 |
| 52-Week High | 5 |
| 52-Week Low | 0.9 |
| Volume | 82,209 |
| Average Volume | 91,839 |
| Market Cap | 5.72M |
| PE | -0.44 |
| EPS | -2.12 |
| Moving Average 50 Days | 1.3 |
| Moving Average 200 Days | 1.66 |
| Change | -0.01 |
If you invested $1000 in Aprea Therapeutics, Inc. (APRE) since IPO date, it would be worth $2.29 as of December 14, 2025 at a share price of $0.938. Whereas If you bought $1000 worth of Aprea Therapeutics, Inc. (APRE) shares 5 years ago, it would be worth $1.63 as of December 14, 2025 at a share price of $0.938.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Dec 09, 2025 1:30 PM GMT
Financing from new and existing healthcare focused investors The proceeds are expected to extend the Company’s cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that period DOYLESTOWN, Pa., Dec. 0
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
GlobeNewswire Inc.
Oct 24, 2025 12:30 PM GMT
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors harboring mutations relevant to
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
GlobeNewswire Inc.
Oct 15, 2025 12:00 PM GMT
ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 monotherapy enrollment paused with strategic focus on high-value combinationCompany is prioritizing its lead program, WEE1 kin